Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Maximizing Impact and Utility of Prognostic Gene Testing in Melanoma and Squamous Cell Carcinoma : Episode 6

Opinion

Video

April 4, 2025

Key Takeaways on GEP Testing in Melanoma and SCC

Author(s):

An expert discusses when gene expression profile (GEP) testing is recommended for melanoma and squamous cell carcinoma (SCC) patients, including cases where it may not be necessary, and provides final thoughts on the utility of GEP testing in risk stratification and making treatment decisions.

EP: 1.Limitations and Challenges in Skin Cancer Staging Systems

EP: 2.Utility of Molecular Testing in Skin Cancer Risk Assessment

EP: 3.Gene Expression Profiling and Other Molecular Tests Utilized for Melanoma and Squamous Cell Carcinoma

EP: 4.Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma

EP: 5.De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC

Now Viewing

EP: 6.Key Takeaways on GEP Testing in Melanoma and SCC

Video content above is prompted by the following:

When do you recommend GEP testing for melanoma and SCC patients? Are there cases where GEP testing is not necessary?
Give your final thoughts on GEP testing for melanoma and SCC and its utility in risk stratification and making treatment decisions.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!